Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension.

Alimentary pharmacology & therapeutics·2026
Same author

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease in human immunodeficiency virus.

World journal of virology·2026
Same author

Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions.

Frontiers in epidemiology·2026
Same author

A Review of Therapies for Primary Biliary Cholangitis.

Gastroenterology & hepatology·2026
Same author

The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease.

Nature communications·2026
Same author

A comprehensive narrative review of artificial intelligence use in the diagnosis and management of metabolic dysfunction-associated steatotic liver disease.

Translational gastroenterology and hepatology·2026

Related Experiment Video

Updated: May 9, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

New therapies for primary biliary cholangitis.

Aalam Sohal1,2, Mariam Alamgir1,3, Kris V Kowdley4,5

  • 1Liver Institute Northwest, 3216 NE 45th Pl Suite 100, Seattle, WA, 98105, USA.

Hepatology International
|May 8, 2026
PubMed
Summary

New treatments like elafibranor and seladelpar offer hope for Primary Biliary Cholangitis (PBC) patients. Ongoing research focuses on improving biochemical response and symptom control for this autoimmune liver disease.

Keywords:
ElafibranorEmerging therapiesIBAT inhibitorsNew therapiesPBCPemafibrateSaroglitazar

Related Experiment Videos

Last Updated: May 9, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Area of Science:

  • Hepatology
  • Autoimmune Liver Diseases
  • Pharmacology

Background:

  • Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease affecting small bile ducts.
  • Ursodeoxycholic acid (UDCA) is a first-line treatment, but 40% of patients show inadequate response or intolerance.
  • Obeticholic acid (OCA) was a second-line option, but its use is restricted due to side effects, particularly in patients with cirrhosis.

Purpose of the Study:

  • To review emerging therapies for Primary Biliary Cholangitis (PBC).
  • To highlight recent advancements in second-line treatment options for PBC patients.

Main Methods:

  • Literature review of current research on novel PBC therapies.
  • Analysis of recently approved and investigational treatments for PBC.

Main Results:

  • Elafibranor and seladelpar were approved in 2024 as second-line PBC treatments.
  • Obeticholic acid (OCA) was withdrawn from the market in 2025.
  • Investigational therapies target biochemical remission, and ileal bile acid transporter (IBAT) inhibitors are being studied for pruritus.

Conclusions:

  • The treatment landscape for PBC is rapidly evolving with new second-line agents.
  • Further research into biochemical response, symptom management, and long-term outcomes is crucial for PBC patients.